Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated
